The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

Risultato della ricerca: Article

73 Citazioni (Scopus)

Abstract

AimsTo assess whether host metabolic factors influence the degree of hepaticsteatosis and fibrosis in patients infected with hepatitis C virus, and toevaluate the impact of anti-viral therapy on insulin resistance andserum levels of adipocytokines.MethodsClinical and biochemical features, anthropometrical characteristics, andlevels of fasting insulin, leptin, adiponectin and resistin were measuredin ‘naı¨ve’ patients with chronic hepatitis C, before, during and aftertherapy with Peg-Interferon-alpha 2a plus Ribavirin.ResultsForty-eightpatientswereincluded(M/F28/20;meanage50.0 12.6years;62.5% genotype-1). Body mass index was 26.4 4.0 kg/m2, and visceralobesity was present in 24 patients. At multivariate analysis (RR; 95% CI),steatosis was associated to older age (1.08; 1–1.18), necroinflammatoryactivity (17.67; 1.6–194.46), and raised insulin levels (1.39; 1.1–1.77).Fibrosis was related to necroinflammatory activity (25.73; 2.54–261.11),and steatosis (6.47; 1.09–38.29). Sustained viral response was achieved by62.5% of patients and was associated with younger age (0.92; 0.85–0.99),genotype non-1 (10.61; 1.52–73.76) and absence of visceral obesity (13.78;2.36–80.29). At the end of follow-up, insulin and the homeostasis modelassesment for insulin resistance were reduced and adiponectin increasedwhencompared withbaseline,all unrelatedtotheoutcome oftreatment.ConclusionsVisceral obesity correlates with the degree of steatosis and fibrosis, andit negatively affects treatment response. Significant changes of insulinresistance and adipocytokines occur under treatment, irrespective of virologicaloutcome.
Lingua originaleEnglish
pagine (da-a)1181-1191
Numero di pagine11
RivistaALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume25
Stato di pubblicazionePublished - 2007

Fingerprint

Adipokines
Abdominal Obesity
Chronic Hepatitis C
Insulin Resistance
Fibrosis
Adiponectin
Insulin
Serum
Genotype
Resistin
Ribavirin
Leptin
Hepacivirus
Fasting
Body Mass Index
Homeostasis
Therapeutics
Multivariate Analysis
Obesity

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cita questo

@article{1ab5feb475b54c5a9c19dfdf6a4e6391,
title = "The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.",
abstract = "AimsTo assess whether host metabolic factors influence the degree of hepaticsteatosis and fibrosis in patients infected with hepatitis C virus, and toevaluate the impact of anti-viral therapy on insulin resistance andserum levels of adipocytokines.MethodsClinical and biochemical features, anthropometrical characteristics, andlevels of fasting insulin, leptin, adiponectin and resistin were measuredin ‘naı¨ve’ patients with chronic hepatitis C, before, during and aftertherapy with Peg-Interferon-alpha 2a plus Ribavirin.ResultsForty-eightpatientswereincluded(M/F28/20;meanage50.0 12.6years;62.5{\%} genotype-1). Body mass index was 26.4 4.0 kg/m2, and visceralobesity was present in 24 patients. At multivariate analysis (RR; 95{\%} CI),steatosis was associated to older age (1.08; 1–1.18), necroinflammatoryactivity (17.67; 1.6–194.46), and raised insulin levels (1.39; 1.1–1.77).Fibrosis was related to necroinflammatory activity (25.73; 2.54–261.11),and steatosis (6.47; 1.09–38.29). Sustained viral response was achieved by62.5{\%} of patients and was associated with younger age (0.92; 0.85–0.99),genotype non-1 (10.61; 1.52–73.76) and absence of visceral obesity (13.78;2.36–80.29). At the end of follow-up, insulin and the homeostasis modelassesment for insulin resistance were reduced and adiponectin increasedwhencompared withbaseline,all unrelatedtotheoutcome oftreatment.ConclusionsVisceral obesity correlates with the degree of steatosis and fibrosis, andit negatively affects treatment response. Significant changes of insulinresistance and adipocytokines occur under treatment, irrespective of virologicaloutcome.",
author = "Almasio, {Pier Luigi} and Amato, {Marco Calogero} and Vito Rodolico and Carla Giordano and Salvatore Petta and Antonio Craxi and {Di Marco}, Vito and Donatella Ferraro and {Lo Iacono}",
year = "2007",
language = "English",
volume = "25",
pages = "1181--1191",
journal = "ALIMENTARY PHARMACOLOGY & THERAPEUTICS",
issn = "0269-2813",

}

TY - JOUR

T1 - The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

AU - Almasio, Pier Luigi

AU - Amato, Marco Calogero

AU - Rodolico, Vito

AU - Giordano, Carla

AU - Petta, Salvatore

AU - Craxi, Antonio

AU - Di Marco, Vito

AU - Ferraro, Donatella

AU - Lo Iacono, null

PY - 2007

Y1 - 2007

N2 - AimsTo assess whether host metabolic factors influence the degree of hepaticsteatosis and fibrosis in patients infected with hepatitis C virus, and toevaluate the impact of anti-viral therapy on insulin resistance andserum levels of adipocytokines.MethodsClinical and biochemical features, anthropometrical characteristics, andlevels of fasting insulin, leptin, adiponectin and resistin were measuredin ‘naı¨ve’ patients with chronic hepatitis C, before, during and aftertherapy with Peg-Interferon-alpha 2a plus Ribavirin.ResultsForty-eightpatientswereincluded(M/F28/20;meanage50.0 12.6years;62.5% genotype-1). Body mass index was 26.4 4.0 kg/m2, and visceralobesity was present in 24 patients. At multivariate analysis (RR; 95% CI),steatosis was associated to older age (1.08; 1–1.18), necroinflammatoryactivity (17.67; 1.6–194.46), and raised insulin levels (1.39; 1.1–1.77).Fibrosis was related to necroinflammatory activity (25.73; 2.54–261.11),and steatosis (6.47; 1.09–38.29). Sustained viral response was achieved by62.5% of patients and was associated with younger age (0.92; 0.85–0.99),genotype non-1 (10.61; 1.52–73.76) and absence of visceral obesity (13.78;2.36–80.29). At the end of follow-up, insulin and the homeostasis modelassesment for insulin resistance were reduced and adiponectin increasedwhencompared withbaseline,all unrelatedtotheoutcome oftreatment.ConclusionsVisceral obesity correlates with the degree of steatosis and fibrosis, andit negatively affects treatment response. Significant changes of insulinresistance and adipocytokines occur under treatment, irrespective of virologicaloutcome.

AB - AimsTo assess whether host metabolic factors influence the degree of hepaticsteatosis and fibrosis in patients infected with hepatitis C virus, and toevaluate the impact of anti-viral therapy on insulin resistance andserum levels of adipocytokines.MethodsClinical and biochemical features, anthropometrical characteristics, andlevels of fasting insulin, leptin, adiponectin and resistin were measuredin ‘naı¨ve’ patients with chronic hepatitis C, before, during and aftertherapy with Peg-Interferon-alpha 2a plus Ribavirin.ResultsForty-eightpatientswereincluded(M/F28/20;meanage50.0 12.6years;62.5% genotype-1). Body mass index was 26.4 4.0 kg/m2, and visceralobesity was present in 24 patients. At multivariate analysis (RR; 95% CI),steatosis was associated to older age (1.08; 1–1.18), necroinflammatoryactivity (17.67; 1.6–194.46), and raised insulin levels (1.39; 1.1–1.77).Fibrosis was related to necroinflammatory activity (25.73; 2.54–261.11),and steatosis (6.47; 1.09–38.29). Sustained viral response was achieved by62.5% of patients and was associated with younger age (0.92; 0.85–0.99),genotype non-1 (10.61; 1.52–73.76) and absence of visceral obesity (13.78;2.36–80.29). At the end of follow-up, insulin and the homeostasis modelassesment for insulin resistance were reduced and adiponectin increasedwhencompared withbaseline,all unrelatedtotheoutcome oftreatment.ConclusionsVisceral obesity correlates with the degree of steatosis and fibrosis, andit negatively affects treatment response. Significant changes of insulinresistance and adipocytokines occur under treatment, irrespective of virologicaloutcome.

UR - http://hdl.handle.net/10447/61944

M3 - Article

VL - 25

SP - 1181

EP - 1191

JO - ALIMENTARY PHARMACOLOGY & THERAPEUTICS

JF - ALIMENTARY PHARMACOLOGY & THERAPEUTICS

SN - 0269-2813

ER -